IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Navigating Warfarin's Pharmacological Maze: A Review of Drug-Drug Interactions

Vishal K R[1]* Syed Muhammad [2]
[1]4th MBBS, Department of Medicine, [2]2nd PharmD,

[1]Department of Medicine, Dr. Chandramma Dayananda Sagar Institute of Medical Education and Research, Devarakaggalahalli, Kanakapura main Road, Harohalli- 562112, Karnataka, India.,

Abstract
Warfarin, a commonly prescribed anticoagulant, has over 250 known drug interactions that can significantly impact its therapeutic efficacy and safety. These interactions can occur with various medications, dietary supplements, and food items, with approximately 120 drugs or foods interacting with warfarin. The concurrent use of potentially interacting drugs during warfarin therapy is a common practice, with about half of patients receiving warfarin being prescribed concomitant drugs with high potential for interactions. These interactions can interfere with the maintenance of the International Normalized Ratio (INR) within the therapeutic range, leading to an increased risk of bleeding events. Studies have shown that the risk of serious bleeding in patients treated with warfarin is significantly higher when they are using potentially interacting drugs, compared to those on warfarin alone. The influence of drug-drug interactions on the risk of cerebral hemorrhage induced by warfarin has also been investigated. In conclusion, warfarin drug interactions are of great clinical importance, as a large number of patients who take concomitant medications that can increase the INR or the risk of bleeding are at risk.

Keywords: ***Warfarin, Anticoagulation therapy, Drug interactions, Pharmacokinetics, Pharmacodynamics, Cytochrome P450 enzymes, Vitamin K antagonists, INR (International Normalized Ratio), Clinical implications, Adverse effects.***

1. Introduction
Warfarin, a commonly prescribed anticoagulant, has numerous drug interactions that impact its effectiveness and safety. These interactions involve various drugs, dietary supplements, and food items, with over 250 known interactions documented[1]. The risk of severe bleeding during warfarin treatment is influenced by drug interactions, and the clinical significance of these interactions continues to be debated[2]. It has been reported that approximately 120 medications or foods interact with warfarin[2]. The potential for drug interactions with warfarin is a cause for concern, and it has been suggested that these interactions might be a major source of bleeding events in patients receiving anticoagulant treatment[10]. Commonly reported interactions include those with anti-infective agents, lipid-lowering drugs, NSAIDs, selective serotonin reuptake inhibitors, amiodarone, omeprazole, fluorouracil, and cimetidine. While some medications like digoxin and furosemide may not have clinically significant interactions with warfarin, they can still affect its absorption and efficacy indirectly[8]. In recent years, direct oral anticoagulants (DOACs) have emerged as alternatives to warfarin due to their more favorable side effect profile and less frequent monitoring requirements[9]. It is crucial to monitor and manage drug interactions involving warfarin carefully, especially in populations with common comorbidities like diabetes, to avoid adverse effects[19]. Pharmacogenetic testing for genes like CYP2C9 and VKORC1 can provide valuable information on individual responses to warfarin, aiding in dose optimization and reducing the risk of adverse events[20,21] . Additionally, patient adherence to warfarin therapy is essential for its effectiveness, with challenges such as clinic visits, dietary restrictions, and concerns about side effects needing to be addressed[22]. Studies have also explored interactions between warfarin and other medications like miconazole, leflunomide, and oseltamivir, highlighting the importance of understanding these interactions to prevent potential complications[23-25]. Furthermore, the

impact of switching from warfarin to direct oral anticoagulants on patient satisfaction and outcomes has been investigated, emphasizing the need for individualized treatment approaches[26].

1.1 Mechanism of Action

Warfarin is an antagonist that inhibits the production of vitamin K by vitamin K epoxide reductase. The reduced form of vitamin K, vitamin KH2 is a cofactor used in the γ-carboxylation of coagulation factors VII, IX, X and thrombin. Carboxylation induces a conformational change that allows the factors to bind to Ca2+ and phospholipid surfaces. Non-carboxylated factors VII, IX, X and thrombin are biologically inactive and therefore function to disrupt the coagulation cascade. Endogenous anticoagulant proteins C and S also require γ-carboxylation to function. This is especially true for thrombin, which must be activated to form a clot. Vitamin K2 is converted to vitamin K epoxide as part of a γ-carboxylation reaction catalyzed by γ-glutamyl carboxylase. Vitamin K epoxide is then converted to vitamin K1 by vitamin K epoxide reductase and then back to vitamin KH2 by vitamin K reductase. Warfarin binds to subunit 1 of the vitamin K epoxide reductase complex and irreversibly inhibits the enzyme, thus stopping the recycling of vitamin K, preventing the conversion of vitamin K epoxide to vitamin K1. This process produces a hypercoagulable state for a short time, where proteins C and S are degraded first with half-lives of 8 and 24 hours, except for factor VII, which has a half-life of 6 hours. Factors IX, X, and finally thrombin are then degraded with half-lives of 24, 36, and 50 hours, leading to a dominant anticoagulation effect. To reverse this anticoagulation, vitamin K must be administered either exogenously or by removing inhibition of vitamin K-epoxide reductase, and time. Must be allowed for the synthesis of new coagulation factors. It takes about 2 days for the synthesis of new coagulation factors in the liver. Vitamin K2, which is functionally identical to vitamin K1, is synthesized by intestinal bacteria, which causes interactions with antibiotics, because elimination of these bacteria can reduce vitamin levels.[12]

Table - Drugs that Show Adverse Effects with Warfarin. These Need to be Avoided and Therapy Should be Modified to Provide a Treatment and Prevent Potential Complications.

May increase INR	**May decrease INR**
Acetaminophen	Antibiotics • Dicloxacillin • Griseofulvin • Nafcillin • Rifampin
Allopurinol	Azathioprine
CVS Medicines| Amiodarone Quinidine Propafenone	Cholestyramine
Androgens • Methyltestosterone • Oxandrolone • Testosterone	Enzyme-inducing antiseizure medications • Carbamazepine • Phenobarbital • Phenytoin
Antibiotics • Cephalosporins • Doxycycline • Fluoroquinolones Ciprofloxacin Levofloxacin Moxifloxacin Norfloxacin • Macrolides Azithromycin Clarithromycin Erythromycin • Metronidazole • Co-trimoxazole| • Penicillins (Exceptions:dicloxacillin and nafcillin) Amoxicillin Amoxicillin-clavulanate • Trimethoprim/sulfamethoxazole • Cefoperazone/sulbactum	Ritonavir
Azole antifungals • Fluconazole • Miconazole • Voriconazole	Saint John's wort
Cancer therapies • Capecitabine • Fluorouracil • Imatinib • Tamoxifen*	Sucralfate
Cholesterol-lowering agents (Exceptions: Cholestyramine) • Fenofibrate • Bezafibrate • Clofibrate • Fluvastatin • Atorvastatin • Gemfibrozil	Vitamin K Supplements

*-

• Lovastatin • Rosuvastatin • Simvastatin	
Cimetidine Salixylates|	Anticoagulants • Urokinase*
Glucocorticoids • Methylprednisolone • Prednisone	Antiplatelet medicines • Aspirin • Varopaxar* • Clopidogrel Dipyridamole • Ticagrelor
Omeprazole	Nonsteroidal anti-inflammatory agents (NSAIDs) • Ibuprofen • Aspirin| • Naproxen • Diclofenac • Indomethacin • Ketoprofen • Piroxicam • Meloxicam • Celecoxib
Selective serotonin reuptake inhibitors (SSRIs) • Duloxetine • Fluoxetine • Fluvoxamine • Venlafaxine	Mifepristone*
Sitaxentan	Omacetaxine*
Tramadol	Hemin*
Streptokinase*	Levothyroxine
Oxatomide*	

Indicates severe risk

Table-1: Drugs that affect INR by reacting with warfarin[15-18] .

2. Discussion

Warfarin is metabolized by the CYP450 liver enzyme complex and eliminated by the kidneys, but each stereoisomer is metabolized differently. The S-isomer is mainly metabolized by CYP2C9 and R-warfarin by CYP3A4[5]. According to Ashwin et al., when certain psychotropic medications such as fluoxetine, fluvoxamine, quetiapine, and valproic acid are started or discontinued in patients receiving warfarin or given to a patient receiving a stable dose of psychotropic medication, the international normalized ratio (INR) must be carefully monitored to ensure it remains within the therapeutic range, as it is metabolized in the liver and highly protein bound and is prone to drug interactions with its relatively narrow therapeutic window puts patients at risk for bleeding or thrombotic complications. Leslie et al. state that the drugs that compete for these cytochromes as substrates or inhibit their activity can increase the plasma concentration and INR of warfarin, which can increase the risk of bleeding[6]. Conversely, drugs that induce these metabolic pathways may decrease warfarin plasma concentrations and INR, which may lead to reduced efficacy. In a study conducted by Maria Rekala et al., they found out that 74.4% of warfarin users were co-prescribed with interacting drugs. Co-prescribing covered 46.4% of the total person-years of warfarin exposure while interacting drugs that should be avoided with warfarin were co-prescribed for 13.4% of warfarin users [10]. Upon exploring natural medicine, Lahan McLauren et al., noticed that the cranberry significantly increased the area under the INR–time curve by 30% when administered with warfarin compared with treatment with warfarin alone. Cranberry did not alter *S*- or *R*-warfarin pharmacokinetics or plasma protein binding but co-administration of garlic did not significantly alter warfarin pharmacokinetics or pharmacodynamics. Both herbal medicines showed some evidence of interactions with warfarin[7]. Most interactions with warfarin are associated with the prescription of NSAIDs in a study conducted in Estonia general hospital by Gavarovski

et al [3]. With any increase in parameters concerning thyroid function, there is a potential for increase in the INR of a patient taking warfarin due to increased catabolism of vitamin K-dependent clotting factors. Cimetidine may increase the INR by inhibiting the metabolism of R-warfarin while concomitant use of salicylates with warfarin can lead to increased bleeding risk because salicylates inhibit platelet aggregation, that in turn can lead to gastric irritation, and result in increased free warfarin due to salicylates having a higher affinity for protein binding sites[11]. As per the study conducted by Anne et al., some of the most commonly given drugs are found to have some reaction with the anticoagulant such as azole antibiotics, macrolides, quinolones, nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, amiodarone, fluorouracil, and co administration with warfarin should be avoided or closely monitored and the most commonly cited mechanisms for interactions with warfarin involved those concerned with stereoselective clearance due to S-enantiomer (ritonavir and cotrimoxazole) or nonstereoselective clearance (simvastatin and terbinafine) or the vitamin K pathway seen in metabolism of green tea[14].

2.2 Warfarin Alternatives

Warfarin alternatives have gained significant attention in recent years, with direct oral anticoagulants (DOACs) emerging as prominent options. DOACs include direct thrombin inhibitors like Dabigatran and Factor Xa inhibitors such as Apixaban, Edoxaban, and Rivaroxaban[27]. These newer agents have been introduced as alternatives to warfarin, aiming to overcome some of its limitations[28]. The shift towards DOACs has been driven by their more favorable safety profiles and reduced need for frequent monitoring compared to warfarin. Additionally, novel anticoagulants have been explored in various clinical scenarios, such as in patients undergoing percutaneous coronary intervention, where regimens combining rivaroxaban with different antiplatelet agents have been studied[29]. The use of DOACs has also been associated with improved patient satisfaction and outcomes compared to warfarin, highlighting their growing importance in clinical practice. Despite the increasing use of DOACs, challenges remain, such as the lack of approved reversal agents for some of these newer anticoagulants[30]. Overall, the landscape of anticoagulation therapy is evolving, with DOACs playing a significant role in providing effective and safe alternatives to traditional agents like warfarin.

3. Conclusion

In conclusion, this literature underscores the clinical importance of warfarin drug interactions, where a large number of patients who take concomitant medications that can increase the INR or the risk of bleeding are reminded that bleeding events are a likely side effect when they combine drugs that interact with warfarin, that can significantly impact the safety and efficacy of anticoagulant therapy that highlights the need for healthcare providers to be vigilant in managing and monitoring drug regimens involving warfarin. Male gender was an independent predictor of severe bleeding as they were the receipt of warfarin-interacting medications at the onset of anticoagulation therapy as per the study conducted by Jonathan et al[6]. The management of drug-drug interactions involving warfarin requires a comprehensive understanding of the potential interactions, individual variability in response, and strategies to optimize therapy while minimizing risks. Healthcare providers should stay vigilant, consider genetic factors, and tailor treatment plans to ensure the safe and effective use of warfarin in clinical practice.

References:

1. Wittkowsky, A., Boccuzzi, S., Wogen, J., Wygant, G., Patel, P., & Hauch, O. (2004). Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 24(12), 1668-1674. https://doi.org/10.1592/phco.24.17.1668.52338
2. Takada, T., Yamanashi, Y., Kentaro, K., Yamamoto, T., Toyoda, Y., Masuo, Y., … & Suzuki, H. (2015). Npc1l1 is a key regulator of intestinal vitamin k absorption and a modulator of warfarin therapy. Science Translational Medicine, 7(275). https://doi.org/10.1126/scitranslmed.3010329
3. Hauta-Aho, M., Tirkkonen, T., Vahlberg, T., & Laine, K. (2009). The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Annals of Medicine, 41(8), 619-628. https://doi.org/10.1080/07853890903186168
4. Jönsson, A., Spigset, O., Jacobsson, I., & Hägg, S. (2006). Cerebral haemorrhage induced by warfarin—the influence of drug–drug interactions. Pharmacoepidemiology and Drug Safety, 16(3), 309-315. https://doi.org/10.1002/pds.1291
5. Kotirum, S., Chaiyakunapruk, N., Jampachaisri, K., Wattanasombat, S., & Rojnuckarin, P. (2006). Utilization review of concomitant use of potentially interacting drugs in thai patients using warfarin therapy. Pharmacoepidemiology and Drug Safety, 16(2), 216-222. https://doi.org/10.1002/pds.1300
6. Lindh, J., Holm, L., Dahl, M., Alfredsson, L., & Rane, A. (2007). Incidence and predictors of severe bleeding during warfarin treatment. Journal of Thrombosis and Thrombolysis, 25(2), 151-159. https://doi.org/10.1007/s11239-007-0048-2

7. Mitchiner, J., Korzeniewski, S., Betten, D., Halasyamani, L., Burns, S., Callahan, C., … & Manthey, C. (2012). Evaluation of the b-safe campaign to reduce clinically significant warfarin–drug interactions among fee-for-service medicare beneficiaries. American Journal of Medical Quality, 27(6), 518-523. https://doi.org/10.1177/1062860612438706
8. Hsu, C., Chen, W., & Sung, S. (2012). Warfarin-induced leukocytoclastic vasculitis: a case report and review of literature. Internal Medicine, 51(6), 601-606. https://doi.org/10.2169/internalmedicine.51.6240
9. Elango, K., Javaid, A., Khetarpal, B., Ramalingam, S., Kolandaivel, K., Gunasekaran, K., … & Ahsan, C. (2021). The effects of warfarin and direct oral anticoagulants on systemic vascular calcification: a review. Cells, 10(4), 773. https://doi.org/10.3390/cells10040773
10. Zhou, H., Patat, A., Parks, V., Buckwalter, M., Metzger, D., & Korth-Bradley, J. (2004). Absence of a pharmacokinetic interaction between etanercept and warfarin. The Journal of Clinical Pharmacology, 44(5), 543-550. https://doi.org/10.1177/0091270004264164
11. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e419S-e496S
12. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):160S-198S. doi: 10.1378/chest.08-0670.
13. Systematic Overview of Warfarin and Its Drug and Food Interactions
14. Anne M. Holbrook, MD, PharmD, MSc, FRCPC; Jennifer A. Pereira, MSc; Renee Labiris, PhD; et alHeather McDonald, MSc; James D. Douketis, MD, FRCPC; Mark Crowther, MD, MSc, FRCPC; Philip S. Wells, MD, FRCPC Arch Intern Med. 2005;165(10):1095-1106. Doi:10.1001/archinte.165.10.1095
15. Greenblatt DJ, von Moltke L. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45:127.
16. Holbrook A, Schulman S, Witt D, et al. Evidenced-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed. Chest 2012; 141:e152S.
17. Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother 2006; 40:2101.
18. Lexi-Interact. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.
19. Ikäheimo, I., Karjalainen, M., Tiihonen, M., Haanpää, M., Kautiainen, H., Saltevo, J., … & Mäntyselkä, P. (2019). Clinically relevant drug-drug interactions and the risk for drug adverse effects among home-dwelling older persons with and without type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 44(5), 735-741. https://doi.org/10.1111/jcpt.12854
20. Flockhart, D., Gage, B., Gandolfi, R., King, R., Lyon, E., Nussbaum, R., … & Watson, M. (2008). Pharmacogenetic testing of cyp2c9 and vkorc1 alleles for warfarin. Genetics in Medicine, 10(2), 139-150. https://doi.org/10.1097/gim.0b013e318163c35f
21. Liu, Y., Jortani, S., Ramey-Hartung, B., Hudson, E., Lemieux, B., & Kong, H. (2011). Genotyping three snps affecting warfarin drug response by isothermal real-time hda assays. Clinica Chimica Acta, 412(1-2), 79-85. https://doi.org/10.1016/j.cca.2010.09.014
22. Kneeland, P. and Fang, M. (2010). Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Preference and Adherence, 51. https://doi.org/10.2147/ppa.s6101
23. Miki, A., Ohtani, H., & Sawada, Y. (2010). Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model. Journal of Clinical Pharmacy and Therapeutics, 36(6), 642-650. https://doi.org/10.1111/j.1365-2710.2010.01229.x
24. Chonlahan, J., Halloran, M., & Hammonds, A. (2006). Leflunomide and warfarin interaction: case report and review of the literature. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 26(6), 868-871. https://doi.org/10.1592/phco.26.6.868
25. Davies, B., Baldó, P., Lennon-Chrimes, S., & Brewster, M. (2010). Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients. British Journal of Clinical Pharmacology, 70(6), 834-843. https://doi.org/10.1111/j.1365-2125.2010.03780.x
26. Hendriks, T., McGregor, S., Rakesh, S., Robinson, J., Ho, K., & Baker, R. (2020). Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism – the swan study. Plos One, 15(6), e0234048. https://doi.org/10.1371/journal.pone.0234048
27. Whitehouse, K., Avula, D., Kahlon, T., Costelle, D., Dunbar-Matos, C., Pahwa, S., … & Slaughter, M. (2022). Apixaban: alternative anticoagulation for heartmate 3 ventricular assist device. Asaio Journal, 68(3), 318-322. https://doi.org/10.1097/mat.0000000000001650

28. Souresrafil, A., Abutorabi, A., Peighambari, M., Noohi, F., & Haghjoo, M. (2022). Cost-effectiveness of new oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in low and middle-income countries: a systematic review. Medical Journal of the Islamic Republic of Iran. https://doi.org/10.47176/mjiri.36.6
29. Pradhan, A., Bhandari, M., Vishwakarma, P., & Sethi, R. (2020). Novel dual therapy: a paradigm shift in anticoagulation in patients of atrial fibrillation undergoing percutaneous coronary intervention. Th Open, 04(04), e332-e343. https://doi.org/10.1055/s-0040-1719081
30. Ho, J., Bari, N., & Riffat, F. (2020). Management of epistaxis in patients on novel oral anticoagulation therapy. The Journal of Laryngology & Otology, 134(4), 316-322. https://doi.org/10.1017/s0022215120000754